Randomised clinical trial: A novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - The results of two double-blind studies Academic Article uri icon

Overview

MeSH Major

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Esomeprazole
  • Esophagitis
  • Heartburn
  • Proton Pump Inhibitors

abstract

  • Rabeprazole-ER is as effective as esomeprazole in healing moderate-severe oesophagitis and achieves similar rates of heartburn resolution. Subgroup analysis suggests the possibility of benefit in severe oesophagitis, but this requires further evaluation (ClinicalTrials.gov: NCT00658528 and NCT00658775).

publication date

  • January 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/j.1365-2036.2010.04516.x

PubMed ID

  • 21114792

Additional Document Info

start page

  • 203

end page

  • 12

volume

  • 33

number

  • 2